Prosensa (RNA +1.7%) jumps on multiple coverage initiations. Leerink, Wedbush, Citi, and...

|About: Prosensa Holding N.V. (RNA)|By:, SA News Editor

Prosensa (RNA +1.7%) jumps on multiple coverage initiations. Leerink, Wedbush, Citi, and JPMorgan start the shares at Outperform (PT, $35), Outperform (PT, $50), Buy (PT $38), and Overweight (PT, $35) respectively. Analysts are generally positive on the DMD treatment drisapersen, under development with GlaxoSmithKline (GSK -0.5%) and see possible approval in H2 2014. The company is essentially in a race to market with Sarepta Therapeutics (SRPT -0.4%), whose eteplirsen shows promise in DMD.